Overactive bladder
Conditions
Interventions
Mirabegron 50 mg is orally administered once daily for 12 weeks.
Imidafenacin 0.1 mg is orally administered twice daily for 12 weeks.
Sponsors
Department of Urology, Hamamatsu University School of Medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)OAB patients (urgency score >= 2 and total score >= 3 in overactive bladder symptom score [OABSS]). 2)Twenty year-old or more patients 3)Postmenopausal women 4)Patients from whom we received written informed consent
Exclusion criteria
Exclusion criteria: 1)Premenopausal women 2)Demonstrable stress urinary incontinence 3)Post-void residual urine volume is more than 100mL, or presence of previous bladder outlet obstruction (BOO) 4)Patients with obvious inflammation, urinary tract infection, urolithiasis or malignant disease of the pelvic organs 5)Patients who have administered prohibited substances 6)Patients with previous pelvic radiation or surgery. 7)Patients who have received prohibited therapy 8)Patients who have contraindication of anticholinergic agents or Mirabegron 9)Patients with severe hepatic or renal dysfunction 10)Patients who have allergies for anticholinergic or beta-adrenergic agents 11)Patients who have received anticholinergic or beta-adrenergic agents within 12 months 12)Patients with severe cardiac dysfunction 13)Patients with arrhythmia 14)Patients with hypokalemia 15)Patients with polyuria 16)Any other patients whom the attending physician considered ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of total overactive bladder symptom score (OABSS) | — |
Countries
Japan
Contacts
Public ContactAtsushi Otsuka
Hamamatsu University School of Medicine Department of Urology
Outcome results
None listed